MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2025 International Congress

    Platelets Lipidome as Potential Biomarker of Parkinson’s Disease

    G. Uras, S. Lucas-Del-Pozo, V. Lentini, F. Fierli, S. Koletsi, D. Hughes, A. Schapira, . (London, United Kingdom)

    Objective: The aim of this proejct is to identify novel biomarkers of Parkinson's disease diagnosis and progression, with a focus on GBA-PD. Background: Our previous…
  • 2025 International Congress

    Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body

    M. Kurihara, T. Matsubara, K. Satoh, A. Arakawa, M. Hara, K. Kanemaru, A. Iwata, S. Murayama, Y. Saito (Tokyo, Japan)

    Objective: Based on the recent recommendations by international neuropathologists [1], we attempted to evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seeding amplification…
  • 2025 International Congress

    Rescuing alpha-synuclein toxicity through neuron-specific enhancement of autophagy

    J. Chua, M. Farah, S. Tewari, A. Parvataneni, V. Dawson, T. Dawson (Baltimore, USA)

    Objective: In the present study, we aim to counteract regulatory and transcriptional modifiers of autophagy to enhance neuroprotective proteostasis and rescue alpha-synuclein (asyn) toxicity in…
  • 2025 International Congress

    ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy

    D. Stamler, C. Wong, P. Trujillo, M. Bradbury, C. Lucas, K. Kmiecik, D. Claassen (Newark, USA)

    Objective: Evaluate the efficacy and safety of ATH434 treatment in individuals with MSA Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder without…
  • 2025 International Congress

    Association Between Heterozygous Loss-of-Function Variants in the MCOLN1 Gene and α-Synucleinopathies

    CX. Ying, XH. Chen, ZD. Cen, W. Luo (Hangzhou, China)

    Objective: To evaluate the association between heterozygous loss-of-function variants in the MCOLN1 gene and α-synucleinopathies. Background: Lysosomes play a crucial role in cellular waste disposal,…
  • 2025 International Congress

    Alpha-Synuclein Amplification Assays Utilizing Real-Time Quaking-Induced Conversion (RT-QuIC) from Non-Invasive Saliva as a Novel Diagnostic Tool for Patients with Parkinson’s Disease

    PRA. Sharma, RK. Dhamija (Delhi, India)

    Objective: The main objective is to evaluate the sensitivity of aSyn-RT-QuIC in diagnosing Parkinson's Disease (PD) from non-invasive saliva. The results will be corroborated in…
  • 2025 International Congress

    The relationship between synuclein-related biomarkers and people with upper-respiratory causes of hyposmia or persistent hyposmia

    E. Brown, T. Tropea, A. Siderowf, L. Heathers, T. Foroud, C. Gochanour, C. Caspell-Garcia, M. Marshall, R. Kurth, T. Simuni, K. Marek, C. Tanner (San Francisco, USA)

    Objective: To determine how smell-testing can enrich screening for individuals with biomarkers related to neuronal alpha-synucleinopathy-related neurodegeneration (NSD). Background: Loss of sense of smell is the…
  • 2025 International Congress

    Mass spectrometry-based screening for α-synuclein bioactive marine natural products

    F. Ferretti, M. Xu, D. Prebble, G. Mellick, A. Carroll (Gold Coast, Australia)

    Objective: This study identifies marine-derived natural products with binding affinity and aggregation-inhibition activity against α-synuclein (α-syn) using a mass spectrometry (MS)-based screening approach. The objective…
  • 2025 International Congress

    The Impact of Non-Motor Symptoms on Quality of Life in Early Parkinson’s Disease: A Prospective Study

    F. Al-Zaidi (Almaty, Kazakhstan)

    Objective: To assess the prevalence and severity of non-motor symptoms (NMS) in early Parkinson’s disease (PD) and their impact on health-related quality of life (HRQoL).…
  • 2025 International Congress

    The A53T mutation in alpha-synuclein impairs astrocytic metabolism and inflammatory response

    S L. Pereira, M. Tziortziou, P. Mulica, S. Delcambre, L. Gallucci, L. Neises, M. Soudy, E. Glaab, M. Mendes, G. Dittmar, J. Meiser, A. Grünewald (Esch-sur Alzette, Luxembourg)

    Objective: This study aims to explore the impact of the A53T alpha-synuclein (α-syn) mutation on astrocytic homeostasis and metabolism in the presence of inflammatory stimuli.…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley